Journey Biosciences (Accelerator)

Company Description: Our flagship biomarker screening detects an individual’s personal risk for diabetes-related kidney disease (DKD) years before any signs or symptoms appear. This early insight enables people with diabetes and their healthcare teams to take action to prevent or delay this condition. One in three adults with diabetes will develop kidney disease and, in 90% of cases, they won’t know they have it until it has advanced to the point where they need dialysis or a kidney transplant to survive, as it develops slowly and without symptoms. NaviDKD identifies high risk of kidney disease before signs or symptoms arise. Proactively assessing risk years in advance of clinical signs and symptoms, NaviDKD provides the opportunity to change the outcome.